Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): A feasibility study by Beckmann, Gabriele et al.
Original Article · Originalarbeit
Onkologie 2006;29:137–142 Published online: March 21, 2006
DOI: 10.1159/000092062
Dr. Gabriele Beckmann
Klinik und Poliklinik für Strahlentherapie
Universität Würzburg, Josef-Schneider-Strasse 11
97080 Würzburg, Germany
Tel. +49 931 20128-891, Fax -396
E-mail beckmann_g@ klink.uni-wuerzburg.de
© 2006 S. Karger GmbH, Freiburg
Accessible online at: 
www.karger.com/onk
Fax +49 761 4 52 07 14
E-mail Information@Karger.de
www.karger.com
Schlüsselwörter
Nicht-kleinzelliges Bronchialkarzinom · Radiochemothera-
pie · Vinorelbin, oral · Cisplatin · Chemokonsolidierung
Zusammenfassung
Hintergrund: Die simultane Radiochemotherapie hat das
Gesamtüberleben beim inoperablen nicht-kleinzelligen
Bronchialkarzinom (NSCLC) Stadium IIIB verbessert. Die
vorliegende Phase-I/II-Studie hatte das Ziel, die Dosis für
orales Vinorelbin in Kombination mit Cisplatin und simulta-
ner Radiotherapie festzulegen. Patienten und Methoden:
Unbehandelte Patienten mit NSCLC Stadium IIIB erhielten
eine simultane Radiochemotherapie mit 66 Gy und 2 Zyklen
Cisplatin/Vinorelbin oral, welches in 3 Dosisstufen verab-
reicht wurde (40, 50 und 60 mg/m2). Im Anschluss daran
waren 2 weitere Zyklen Chemotherapie zur Konsolidierung
vorgesehen. Studienziel war die Festlegung der maximal to-
lerablen Dosis von oralem Vinorelbin in Kombinationsche-
motherapie simultan zur Bestrahlung. Ergebnisse: 11 Pa-
tienten (Stadium IIIB) wurden in die Studie eingeschlossen.
Die mediane Radiotherapiedosis betrug 66 Gy. Als Grad-3/4-
Nebenwirkungen traten Neutropenie, Ösophagitis, Gastritis
und febrile Neutropenie auf. Dosislimitierend unter simulta-
ner Radiochemotherapie war die Ösophagitis. 9 Patienten
erhielten Chemokonsolidierung, wobei lediglich Grad-3/4-
Hämatotoxizität auftrat. Die Gesamtansprechrate betrug
73%. Schlussfolgerung: Bei einer simultanen Radiochemo-
therapie mit 66 Gy ist Vinorelbin oral 50 mg/m2 (Tag 1, 8, 15
für 4 Wochen) in Kombination mit Cisplatin 20 mg/m2 (Tag
1–4) die empfohlene Dosierung. Dieses Schema findet An-
wendung in einer Phase-III-Studie, die den Nutzen einer
Konsolidierungschemotherapie bei Patienten, die nach si-
multaner Radiochemotherapie nicht progredient sind, tes-
ten soll.
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Summary
Background: Concurrent chemoradiotherapy has improved
survival in inoperable stage III non-small cell lung cancer
(NSCLC). This phase I trial was performed in order to estab-
lish a dose recommendation for oral vinorelbine in combi-
nation with cisplatin and simultaneous radiotherapy. Pa-
tients and Methods: Previously untreated patients with
stage IIIB NSCLC received concurrent chemoradiotherapy
with 66 Gy and 2 cycles of cisplatin and oral vinorelbine
which was administered at 3 different levels (40, 50 and
60 mg/m2). This was to be followed by 2 cycles of cis-
platin/vinorelbine oral consolidation chemotherapy. The
study goal was to determine the maximal recommended
dose of oral vinorelbine during concurrent treatment. Re-
sults: 11 stage IIIB patients were entered into the study. The
median radiotherapy dose was 66 Gy. Grade 3–4 toxicity in-
cluded neutropenia, esophagitis, gastritis and febrile neu-
tropenia. The dose-limiting toxicity for concurrent chemora-
diotherapy was esophagitis. 9 patients received consolida-
tion chemotherapy, with neutropenia and anemia/thrombo-
cytopenia grade 3 being the only toxicities. The overall
response was 73%. Conclusion: Oral vinorelbine 50 mg/m2
(days 1, 8, 15 over 4 weeks) in combination with cisplatin 
20 mg/m2 (days 1–4) is the recommended dose in combina-
tion with radiotherapy (66 Gy) and will be used for concur-
rent chemoradiotherapy in a forthcoming phase III trial test-
ing the efficacy of consolidation chemotherapy in patients
not progressing after chemoradiotherapy.
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Introduction
Combined modality treatment including radiotherapy and
chemotherapy has improved survival for patients with inoper-
able stage IIIA/B non-small cell lung cancer (NSCLC) in good
physical condition [1–4]. Induction chemotherapy has been
able to reduce distant metastasis in some trials [5] but had no
influence on local control of the primary tumor. Chemothera-
py given concurrently with radiotherapy has shown to prolong
local control in-field [6, 7] as well as progression-free survival
[8]. At present, simultaneous radiotherapy and full-dose
chemotherapy is the most effective treatment which is, howev-
er, limited by increased acute toxicity [9–11].
The combination of cisplatin with 3 modern cytotoxic agents
(gemcitabine, paclitaxel and vinorelbine) given as induction
chemotherapy and followed by the same drugs concurrent
with radiotherapy was tested in the study CALBG 9431. Cis-
platin/vinorelbine was thought to show the most favorable ef-
ficacy/toxicity profile [12]. Vinorelbine is available in oral as
well as intravenous form, with proven efficacy in NSCLC [13]
and stable absorption from the digestive tract [14]. The ad-
ministration of oral chemotherapy concurrent with radiother-
apy is attractive in an outpatient setting, but the dose for oral
vinorelbine in combination with cisplatin and concurrent
chemoradiotherapy is not yet established. We conducted a
phase I clinical trial to define the maximum tolerated dose for
oral vinorelbine and establish a dose recommendation for a
projected phase III trial.
Patients and Methods
Patients aged between 18 and 70 years with a good performance status
(Karnofsky index ≥ 80%) and histologically or cytologically proven and
previously untreated inoperable NSCLC stage IIIA/B (only N2) were eligi-
ble for enrolment in this study. All patients were requested to have at least 
1 measurable lesion according to RECIST criteria, adequate pulmonary
function, normal blood cell counts, no weight loss of > 10% during the last 
3 months and a life expectancy of > 12 weeks. Required laboratory tests in-
cluded total bilirubin (≤ 1.5), transaminases (≤ 2.5) and alkaline phos-
phatase (≤ 5 times the upper institutional limit) as well as normal creatinine
and/or a creatinine clearance of ≥ 65 ml/min. Patients with superior vena
cava syndrome, pre-existing pleural or pericardial effusion or ascites, severe
comorbid illness, sensory neuropathy > grade I and prior malignancy other
than in situ cervical carcinoma or skin basal cell cancer were excluded. The
protocol was performed in accordance with the Helsinki Declaration and
approved by the Ethics Committee of each participating Center. All pa-
tients gave written informed consent. Pretreatment evaluation included
medical history, complete physical and laboratory examination, electrocar-
diogram, bronchoscopy, pulmonary function, chest and abdominal comput-
ed tomography (CT) scan, brain CT or magnetic resonance imaging (MRI),
bone scan and X-ray of hot spots. Hematology including differential was
done before each administration of vinorelbine. Clinical examinations and
serum chemistry were carried out before day 1 of each chemotherapy cycle.
Study Design
The trial was planned as a multicenter, open-label, non-randomized phase
I/II study of full-dose chemotherapy with oral vinorelbine in combination
with cisplatin concurrent with radiotherapy, followed by consolidation
chemotherapy with oral vinorelbine and cisplatin for inoperable, locally
advanced non-metastasized NSCLC. The study flow chart is depicted in
figure 1. Secondary objectives were to estimate the overall response rate
and to evaluate the feasibility of an additional 2 cycles of consolidation
chemotherapy with cisplatin and oral vinorelbine after concurrent
chemoradiotherapy.
Simultaneous Chemoradiotherapy
2 cycles of oral vinorelbine and cisplatin were given together with radio-
therapy. Oral vinorelbine was tested in 3 dose levels: 40 mg/m2 in level 1,
50 mg/m2 in level 2 and 60 mg/m2 in level 3, administered on days 1, 8, 15
and 29, 36, 43. Cisplatin 20 mg/m2 was given intravenously on days 1–4
and 29–32 after oral vinorelbine. Prophylactic antiemesis included a 5HT3
antagonist. Radiotherapy was delivered 1–2 h after drug administration.
Megavoltage radiotherapy started concomitantly with chemotherapy. CT-
based treatment planning and 3D-conformal techniques were mandatory.
The target volume was restricted to the primary tumor as seen in the lung
window of the planning CT scan and macroscopically involved lymph
node compartments (gross tumor volume, GTV). Lymph nodes were de-
fined as involved if larger than 1.5 cm, in case of central hypodensity or if
multiple nodes of > 1 cm were present in the same compartment. The
planning target volume (PTV) encompassed the GTV with a lateral mar-
gin of 1 cm and a 1.5 cm margin in the cranio-caudal direction.
66 Gy specified according to ICRU 50 (International Commission on Ra-
diation Units and Measurements) were given in 2 Gy single fractions 
5 times a week. A radiotherapy dose increase of up to 10% was at the dis-
cretion of the treating radiotherapist. The PTV was reduced after 50 Gy
to boost only macroscopic disease. Oral vinorelbine given concurrently
with radiotherapy was escalated in 3 dose levels. At least 3 patients were
treated at each dose level. The next dose level was not opened until all 
3 patients entered at a specific dose level had finished simultaneous
chemoradiotherapy without reaching dose-limiting toxicity. If 1 of the 
3 patients experienced a dose-limiting toxicity, 3 more patients were en-
tered at the same dose level. If a second patient experienced dose-limiting
toxicity, dose escalation was stopped and the maximal recommended dose
was defined as the preceding level. Toxicity was graded using National
Cancer Institute (NCI) Common Toxicity Criteria, version 2.0. For pneu-
monitis, the Radiation Oncology Treatment Group (RTOG) scaling was
used. Dose limiting toxicities were defined as grade 4 neutropenia, febrile
neutropenia (Pizzo definition), grade 4 or symptomatic grade 3 thrombo-
cytopenia, grade 3/4 esophagitis, grade 3/4 pneumonitis, neurotoxicity
> grade 2, any organ toxicity > grade 2 (excluding nausea, vomiting and
alopecia) and treatment interruption > 2 weeks.
Consolidation Chemotherapy
Patients without progressive disease confirmed by re-staging 4 weeks after
simultaneous chemoradiotherapy received 2 3-week cycles of consolida-
tion chemotherapy with oral vinorelbine 60 mg/m2 days 1 and 8 and cis-
platin 80 mg/m2 day 1 for the first cycle. If no grade 3/4 neutropenia oc-
curred during the first consolidation cycle, oral vinorelbine 80 mg/m2 days
1 and 8 was given during the second cycle with the same dose of cisplatin.
Response was assessed according to RECIST criteria, 4–6 weeks after the
end of chemoradiotherapy and 4 weeks after end of consolidation
chemotherapy by chest and abdominal CT scans. A final evaluation of
toxicity was performed within 30 days of the last administration of
chemotherapy.
Results
From July 2003 to June 2004, 11 patients, 7 male and 4 female,
were entered into the study. 3 patients were treated in both
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level 1 and 2, and 5 patients were treated in level 3 at which
dose limiting toxicity was evidenced in 4 patients. As a result,
the study recruitment was closed. The mean patient age was
57 years (43–70), and the mean Karnofsky index was 90%
(80–100%). All patients were NSCLC stage IIIB at inclusion.
Histological subtypes included adenocarcinoma in 6 patients
and squamous cell carcinoma in 5 patients. PET staging was
not mandatory but was performed in 8 patients. All patients
were included in the intent-to-treat analysis and analyzed for
safety and toxicity. 
In our protocol, esophagitis was the dose-limiting toxicity
which occurred at level 3. Therefore the recommended dose
has been defined as 50 mg/m2 of oral vinorelbine in combina-
tion with cisplatin given concurrently with radiotherapy. 3 of 
5 patients in the third dose level developed esophagitis grade 3
already during the first cycle of simultaneous chemotherapy,
resulting in the entire treatment being discontinued in 1 pa-
tient and chemotherapy being stopped in another patient who
was able to finish radiotherapy but required parenteral nutri-
tion beyond the end of radiotherapy. The third patient re-
ceived the second cycle of concomitant chemotherapy and
again developed esophagitis grade 3 as a result, which was the
same in another patient who had esophagitis grade 1 previ-
ously. One of these patients suffered from prolonged
esophagitis during consolidation chemotherapy (grade 2 dur-
ing the first cycle, grade 1 during the second cycle). Dysphagia
was mild in dose level 1 and 2, and patients were able to eat a
regular diet until the end of concomitant chemoradiotherapy.
Weight loss occurred only in level 3 (2 cases, grade 1), and 
1 patient at level 3 developed gastritis grade 3. Nausea and
vomiting were associated predominantly with cisplatin in both
level 1 and 2, given on days 1–4 of each cycle. In level 3, nau-
sea/vomiting appeared also after oral vinorelbine. Constipa-
tion was a rare event and was managed by consumption of
fiber. Nephrotoxicity grade 2 caused by application of cis-
platin occurred in 1 patient during simultaneous chemoradio-
therapy and persisted during consolidation chemotherapy. 
3 patients experienced a non-recurring event of sudden tho-
racic pain without obvious correlation to drug administration,
which dissolved spontaneously after a number of hours. Myo-
cardial ischemia was ruled out. Neutropenia grade 3 was seen
in 1 of 3 patients in dose level 2, only during cycle 1. In level 3,
3 out of 5 patients had neutropenia grade 3/4. No grade 3/4
anemia or thrombocytopenia occurred (table 1). One patient
presented with 2 episodes of febrile neutropenia (concurrent
treatment cycle 2 and during consolidation chemotherapy
cycle 4).
Toxicity during consolidation chemotherapy was assessed in 
9 patients receiving consolidation chemotherapy. Tolerance
was influenced by the dose level of previous concurrent
chemoradiotherapy. Patients treated at level 1 passed through
consolidation chemotherapy without major events. Dose es-
calation of oral vinorelbine from 60 to 80 mg/m2 was possible
in all patients, except for 1 patient treated in level 1 who de-
veloped neutropenia grade 3. Hematological toxicity was
more pronounced in levels 2 and 3. Following level 2, all 3 pa-
tients had neutropenia grade 3/4, with anemia and thrombocy-
topenia grade 3 showing in 1 patient. Following level 3, 1 of 
3 patients receiving consolidation had neutropenia grade 4.
Non-hematological toxicity consisted mainly of nausea grade
1/2 in all patients. Pneumonitis grade 2 developed in 1 patient
(dose level 2) 3 months after the end of radiotherapy. CT
scans during follow-up showed fibrotic changes in 2 other pa-
tients (level 1 and 3, respectively) who required no treatment.
Treatment Delivery
All patients entered in level 1 and 2 completed radiotherapy
and the 4 scheduled cycles of chemotherapy, with a once of
omission of day-15 oral vinorelbine according to protocol dur-
ing concomitant treatment due to neutropenia grade 3. In
level 3, chemotherapy was stopped after cycle 1 in 2 patients
because of esophagitis grade 3. Both patients were continued
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 Fig. 1. Study flow chart.
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on radiotherapy. Therefore, all patients received ≥ 66 Gy
(mean dose 66.3 Gy). Oral vinorelbine on day 8 was omitted
once during consolidation after concurrent chemoradiothera-
py at level 3 because of increased of acute-phase proteins and
suspected infection.
Response evaluation was possible in 9 patients after concur-
rent chemoradiotherapy (2 patients in level 3 were taken off
the study due to toxicity) and in 8 patients after both concur-
rent chemoradiotherapy and consolidation chemotherapy.
After concurrent chemoradiotherapy, partial remission was
achieved in 8 patients, and 1 patient had stable disease. After
consolidation chemotherapy, 4 patients were in complete re-
mission of both the primary tumor and mediastinal lymph
node metastases, and 4 patients had a partial remission. The
patients in the recommended dose level responded with 1
complete and 2 partial remissions. After a median follow-up
of 13.4 months (4.6–19.2), 5 patients were still alive, 2 of them
in stable partial and complete remission, respectively. 6 pa-
tients died, 1 because of bacterial pneumonia and 5 because of
progression. 5 patients with local control in-field developed
distant metastases, 3 of them in the brain and 2 of them in the
lung. Only 1 patient had in-field progression.
Discussion
In locally advanced inoperable NSCLC the combination of ra-
diotherapy with chemotherapy seems a logical step to enhance
efficacy of local treatment and treat occult distant metastasis.
The optimal way to deliver chemotherapy is concurrent with
radiotherapy as seen in several randomized controlled trials
[9–11, 15]. The combination of cisplatin and vinorelbine
showed a favorable toxicity profile when given together with
radiotherapy and after 2 cycles of induction chemotherapy
with the same drugs [12]. Primary chemoradiotherapy with vi-
norelbine and a platinum compound was feasible and well tol-
erated with good results in high- risk patients [16].
The dose of intravenous vinorelbine in advanced NSCLC
commonly used as monotherapy or in combination with cis-
or carboplatin is 25–30 mg/m2 per week or administrated on
days 1 and 8 per 3–4-week cycle [17]. In combination with
concurrent radiotherapy, lower doses are given beginning at
12.5 mg/m2 in different schedules or even 4 mg/m2 daily if
used as radiosensitizer [18]. Oral vinorelbine is effective in
NSCLC but exerts slightly higher gastrointestinal toxicity.
Crossover studies assessing the bioavailability of oral and in-
travenous vinorelbine [19] showed that an oral dose of 
80 mg/m2 resulted in similar exposure as the intravenous dose
of 30 mg/m2 and that the oral dose of 60 mg/m2 is comparable
to the intravenous dose of 25 mg/m2 which is the dose com-
monly used in combination regimens [20]. Therefore, we de-
cided to define the highest level in this phase I trial as a dose
of oral vinorelbine of 60 mg/m2 and to initiate the trial with a
lower dose of 40 mg/m2 corresponding to approximately to
15 mg/m2 of intravenous vinorelbine and escalate the dose
over a total of 3 levels.
While neutropenia turned out to be the dose-limiting toxicity
for vinorelbine in most dose-finding studies with chemothera-
py alone, esophagitis is the common toxicity with concurrent
chemoradiotherapy. In our trial, reduced radiotherapy target
volumes supported by additional information from pretreat-
ment PET scans were used and involved areas were covered
Table 1: Toxicity (per cycle)
Toxicity Level 1: 40 mg/m2; patients, n Level 2: 50 mg/m2; patients, n Level 3: 60 mg/m2; patients, n
  
Concurrent CR Consolidation C Concurrent CR Consolidation C Concurrent CR Consolidation C
     
Grade Grade Grade Grade Grade Grade Grade Grade  Grade Grade Grade Grade
1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4
Nausea 2/6 – 1/6 – 5/6 – 6/6 – 7/8 – 6/6 –
Vomiting 2/6 – 1/6 – 4/6 – 3/6 – 5/8 – 3/6 –
Gastritis – – – – – – – – – 1/8 – –
Constipation 1/6 – – – 2/6 – 3/6 – 2/8 – 1/6 –
Nephrotoxicity – – – – – – – – 1/8a – – –
Fatigue 3/6 – 2/6 – 2/6 – 2/6 – 3/8 – 2/6 –
Weight loss – – – – – – – – 2/8 – – –
Esophagitis 6/6 – – – 6/6 – – – 3/8 5/8 2/6 –
Anemiab – – – 1/6 – – – 2/6 – – – –
Leucopeniab – – – – – 1/6 – 3/6 – 3/8 – 1/6
Thrombopeniab – – – – – – – 1/6 – – – –
CR = Chemoradiotherapy, C = chemotherapy.
aUnlikely related to vinorelbine oral.
bOnly grade 3 and 4 given (see text).
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with only moderate safety margins. Nevertheless, esophagitis
was the dose-limiting toxicity. 3 patients entered on level 3 had
esophagitis grade 3 early during cycle 1 and 1 patient during
cycle 2, compared to none of the 6 patients included in levels 
1 and 2. Esophagitis grade 3 was reversible in all cases, but in-
tensive supportive therapy was required. So far, no late toxici-
ty, such as esophageal strictures, were seen in the patients still
alive. In CALBG 9431, esophagitis grade 3/4 was 25% with 
vinorelbine/cisplatin, but 39% with paclitaxel/cisplatin and 
52% with gemcitabine/cisplatin. In this trial, vinorelbine was
given intravenously at 15 mg/m2 on days 1 and 8 together with
cisplatin 80 mg/m2 on day 1 in a 3-week cycle during concomi-
tant chemoradiotherapy [12], corresponding to 40 mg/m2 of
oral vinorelbin. Gastrointestinal toxicity was mild and did not
interfere with intake of the oral drug. Nevertheless, prophy-
lactic antiemesis with a 5HT3 antagonist is recommended and
was strictly administered in this trial. Hematotoxicity was not
a major problem during concurrent chemoradiotherapy. Ane-
mia and thrombocytopenia were rare and only reached grade
1/2. There were 2 episodes of febrile neutropenia both in the
same level 3 patient.
Consolidation chemotherapy with a 4-week break after con-
current chemoradiotherapy was feasible in all patients at level
1 and 2. At level 3, only 3 out of 5 patients received consolida-
tion chemotherapy therapy. 2 patients did not receive consoli-
dation, as chemotherapy had been stopped earlier due to long-
lasting esophagitis grade 3, and were taken off protocol. There
were 3 cases of postradiation pneumonitis with 1 patient re-
quiring active treatment with high-dose steroids. This does not
differ from conventional radiotherapy to this dose level.
The overall response to therapy was good with 8 patients
reaching partial response at the end of concurrent treatment.
At the end of consolidation, 4 patients were in complete re-
sponse and 4 in partial response. Local progression was seen
only in 1 patient during follow-up. As expected in locally ad-
vanced NSCLC, a high proportion of patients developed sys-
temic progression. 3 patients developed metastasis to the
brain. All patients had local control of the primary tumor.
This observation is in line with the results of other trials [5, 9,
21, 22] and raises the question of prophylactic cranial irradia-
tion in a subgroup of patients with NSCLC and documented
complete or near complete response [23].
Conclusion
According to the results of this phase I trial, vinorelbine oral
60 mg/m2 given on days 1, 8, 15 concurrently with cisplatin and
conformal radiotherapy is the maximum tolerated dose, with
esophagitis being the dose-limiting toxicity. Therefore, vi-
norelbine oral 50 mg/m2 is the recommended dose for our
planned phase III trial which is designed to evaluate the role
of consolidation chemotherapy after concomitant chemora-
diotherapy using 2 cycles of chemotherapy given at full dose.
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